Table 3.
Distribution of HR-HPV combinations by histological grade stratified by the number of concurrent infections (Guadeloupe, 2014–2016)
| 1 virus infection | 2–3 virus infections | > 3 virus infections | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CIN2/3 | Invasive cancers | CIN2/3 | Invasive cancers | CIN2/3 | Invasive cancers | ||||
| N = 32 | N = 2 | p | n = 49 | n = 17 | p | n = 81 | n = 7 | p | |
| HR-HPV combinations, n(%) | |||||||||
| 1HR | 29 | 2 | 19 | 8 | 0 | 0 | |||
| HPV16 | 20 (69) | 2 (100) | 0.28 | 11 (22) | 4 (24) | 1 | 0 | 0 | |
| HPV33 | 1 (3.4) | 0 (0) | 0.80 | 0 | 0 | ||||
| HPV35 | 7 (24) | 0 (0) | 0.45 | 1 (2) | 2 (12) | 0.16 | 0 | 0 | |
| HPV51 | 1 (3.4) | 0 (0) | 0.80 | 5 (4) | 2 (12) | 1 | 0 | 0 | |
| HPV56 | – | – | – | 2 (4) | 0 (0) | 1 | 0 | 0 | |
| 2 or 3 HR | – | – | 29 | 9 | 51 | 2 | |||
| HPV16 + 1 other HR * | – | – | – | 5 (10) | 1 (6) | 1 | 3 (4) | 0 (0) | 1 |
| HPV[18–56] | – | – | – | 1 (2) | 2 (12) | 0.16 | 2 (2) | 0 (0) | 1 |
| HPV[31–33] + 1 other HR | – | – | – | 4 (8) | 2 (12) | 0.64 | 32 (40) | 1 (14) | 0.25 |
| HPV [31–52] + 1 other HR | – | – | – | 14 (29) | 1 (6) | 0.09 | 6 (7) | 1 (14) | 0.45 |
| HPV[39–45] + HPV68 | – | – | – | 2 (4) | 1 (6) | 1 | 2 (2) | 0 (0) | 1 |
| More than 3 HR | – | – | – | – | – | – | 29 | 5 | |
| HPV[31–33] + 2 or more other HR * | – | – | – | – | – | – | 19 (23) | 4 (57) | 0.07 |
| HPV{16–52] + 2 or more other HR * | – | – | – | – | – | – | 4 (5) | 0 (0) | 1 |
| HPV[39–68] + 2 or more other HR* | – | – | – | – | – | – | 4 (5) | 0 (0) | 1 |
| HPV[33–52–58-68] | – | – | – | – | – | – | 3 (4) | 0 (0) | 1 |
Other HR-HPV found in association with theses main combinations, involved 2 or 3 of the following HPV genotypes: 18, 35, 45, 51, 56, 58, 59, 68